Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

The TRAIL to selective tumor death

Nature Medicine volume 5, pages 146–147 (1999)Cite this article

Abstract

TNF–related apoptosis–inducing ligand has selective antitumor activity in mice without causing toxic side effects and may have potential as a cancer therapeutic (157–163).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Coley, W.B. Contribution to the knowledge of sarcoma. Ann. Surg. 14, 199–220 (1891).

  2. Vassalli, P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10, 411–452 (1992).

    Article  CAS  Google Scholar 

  3. Walczak, H. et al. Tumoricidal activity of TRAIL in vivo. Nature Med. 5, 157–163 (1999).

    Article  CAS  Google Scholar 

  4. Smith, C.A., Farrah, T. & Goodwin, R.G. The TNF–receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 76, 959–962 (1994).

    Article  CAS  Google Scholar 

  5. Ashkenazi, A. & Dixit, V.M. Death receptors: Signaling and modulation. Science 281, 1305–1308 (1998).

    Article  CAS  Google Scholar 

  6. Schneider, P. et al. Conversion of membrane–bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187, 1–9 (1998).

    Article  Google Scholar 

  7. Wiley, S.R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673–682 (1995).

    Article  CAS  Google Scholar 

  8. Griffith, T.S. & Lynch, D.H. TRAIL: A molecule with multiple receptors and control mechanisms. Curr. Opin. Immunol. 10, 559–563 (1998).

    Article  CAS  Google Scholar 

  9. Irmler, M. et al. Inhibition of death receptor signals by cellular FLIP. Nature 388, 190–195 (1997).

    Article  CAS  Google Scholar 

  10. Pan, G. et al. An antagonist decoy receptor and a death domain–containing receptor for TRAIL. Science 277, 815– 818 (1997).

    Article  CAS  Google Scholar 

  11. Sheridan, J.P. et al. Control of TRAIL–induced apoptosis by a family of signaling and decoy receptors. Science 277, 818–821 (1997).

    Article  CAS  Google Scholar 

  12. Wu, G.S. et al. KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene [letter]. Nature Genet. 17, 141–143 (1997).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Geneva University Hospital, Geneva, 1211, Switzerland

    Lars E. French

  2. Institute of Biochemistry Lausanne University, Epalinges, 1066, Switzerland

    Jürg Tschopp

Authors
  1. Lars E. French
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jürg Tschopp
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

French, L., Tschopp, J. The TRAIL to selective tumor death. Nat Med 5, 146–147 (1999). https://doi.org/10.1038/5505

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/5505

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing